Biohaven Pharmaceutical Holding Company Ltd. logo
Biohaven Pharmaceutical Holding Company Ltd. BHVN
$ 12.36 -9.65%
report update icon

Quarterly report 2022-Q2
added 06-06-2026

Biohaven Pharmaceutical Holding Company Ltd. Total Assets | BHVN

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.
Main categories of assets
Current assets (used within one year):
  • Cash and cash equivalents
  • Accounts receivable (amounts owed by customers)
  • Inventory of goods, raw materials, and supplies
  • Short-term investments
Non-current assets (used for more than one year):
  • Fixed assets (buildings, machinery, equipment)
  • Intangible assets (brands, patents, software)
  • Long-term investments
  • Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Biohaven Pharmaceutical Holding Company Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
1.08 B 687 M 344 M 290 M 147 M 27 M 1.89 M - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
1.08 B 1.89 M 368 M

Quarterly Total Assets Biohaven Pharmaceutical Holding Company Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - 1.39 B 1.37 B 1.08 B 1.13 B 846 M 1 B 687 M 782 M 424 M 533 M 344 M 439 M 491 M 245 M 290 M 195 M 239 M 126 M 147 M 185 M 214 M 60.2 M 27 M 27 M 27 M 27 M - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
1.39 B 27 M 474 M

Total Assets of other stocks in the Biotechnology industry

Issuer Total Assets Price % 24h Market Cap Country
Lipocine Lipocine
LPCN
17 M $ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
138 M $ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
231 M $ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
1.26 B $ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
28.2 M $ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
119 M $ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
244 M $ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
40.7 B $ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
92.1 M $ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
1.11 B $ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
82.3 M $ 2.89 -5.56 % $ 227 M israelIsrael
Lantern Pharma Lantern Pharma
LTRN
11 M $ 0.25 -13.67 % $ 2.72 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
198 M $ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
43.5 M $ 0.77 4.74 % $ 241 M usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
20.2 M $ 0.35 -10.37 % $ 33.6 M canadaCanada
Minerva Neurosciences Minerva Neurosciences
NERV
98 M $ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
4.63 B $ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
67.8 M $ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
327 M $ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
88.1 M $ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
771 M $ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
185 M $ 1.53 -8.68 % $ 555 M usaUSA
Moleculin Biotech Moleculin Biotech
MBRX
22.1 M $ 7.73 -2.59 % $ 9.16 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
14.2 T $ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
688 M $ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
404 M $ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
257 M $ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
668 M $ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
543 B $ 37.8 -2.82 % $ 168 B danmarkDanmark
Marker Therapeutics Marker Therapeutics
MRKR
19.1 M $ 1.1 -17.05 % $ 16.8 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
1.14 B $ 15.62 -1.01 % $ 1.68 B usaUSA
Replimune Group Replimune Group
REPL
332 M $ 19.07 -0.83 % $ 1.77 B usaUSA
NextCure NextCure
NXTC
22.6 M $ 6.62 -2.43 % $ 35.2 M usaUSA
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
330 M $ 1.95 -7.82 % $ 217 M usaUSA
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
117 M $ 0.87 -33.79 % $ 45.7 M usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
7.88 B $ 553.08 -1.08 % $ 24.5 B usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
533 M $ 7.0 -2.1 % $ 609 M usaUSA
Kymera Therapeutics Kymera Therapeutics
KYMR
1.74 B $ 115.19 -3.52 % $ 9.73 B usaUSA
Oragenics Oragenics
OGEN
10.1 M $ 0.16 -6.16 % $ 345 K usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
151 M $ 2.2 -5.98 % $ 286 M usaUSA
Passage Bio Passage Bio
PASG
25.2 M $ 3.94 9.14 % $ 12.6 M usaUSA
Vaxcyte Vaxcyte
PCVX
3 B $ 55.37 -5.12 % $ 7.54 B usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
621 M $ 16.11 1.26 % $ 2.76 B usaUSA
Precigen Precigen
PGEN
156 M $ 4.21 1.08 % $ 1.32 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
1.96 B $ 6.94 -0.57 % $ 956 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
21.5 M $ 0.66 -7.55 % $ 3.95 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
938 M $ 300.01 -3.5 % $ 6.75 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
141 M $ 3.22 -1.08 % $ 248 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
113 M $ 1.02 -2.38 % $ 107 M niderlandNiderland
Ocular Therapeutix Ocular Therapeutix
OCUL
808 M $ 5.57 -5.03 % $ 1.04 B usaUSA